Cambridge, United Kingdom

Miles Stuart Congreve

This inventor holds 97 USPTO granted patents and 30 published patent applications, plus 1 CIPO patent and 40 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D401-14). Top assignees: Heptares Therapeutics Limited, Astex Therapeutics Limited, Nxera Pharma UK Limited. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miles Stuart Congreve. Retrieved from https://idiyas.com/inventor/miles-stuart-congreve

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 97 

% Patents Active = 85.6

 

 

Average Co-Inventor Count = 5.4

ph-index = 14

Forward Citations = 695(Granted Patents)

Forward Citations (Not Self Cited) = 356(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • Royston, GB (2013 - 2014)
  • Melbourn, GB (2014)
  • Hertfordshire, GB (2014 - 2016)
  • Welwyn Garden City, GB (2017 - 2019)
  • Welwyn Garden, GB (2017 - 2019)
  • Cambridge, GB (2006 - 2024)
  • Cambridgeshire, GB (2024)

Company Filing History:


Years Active: 2006-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pharmaceutical Compounds
CGRP Antagonists
Muscarinic Receptor Agonists
Triazolone Compounds
GLP-1 Receptor Antagonists
Prostaglandin E2 Receptor Agonists
Morpholine Derivatives
Cyclohexapeptides
Pyrazole Derivatives
1,2,4-Triazine Compounds
Bicyclic AZA Compounds
Orexin Receptor Antagonists
97 patents (USPTO):Explore Patents

Title: Innovation and Contributions of Miles Stuart Congreve

Introduction

Miles Stuart Congreve is a distinguished inventor based in Cambridge, GB, known for his remarkable contributions to the field of pharmacology and medicinal chemistry. With an impressive portfolio of 86 patents, Congreve has been at the forefront of developing novel compounds aimed at addressing various medical disorders.

Latest Patents

Among his latest patents, Congreve has introduced innovative CGRP antagonist compounds. These disclosures relate to novel compounds of Formula (1a) and their use in treating, preventing, ameliorating, controlling, or reducing the risk of disorders associated with CGRP receptors. Additionally, he has worked on quinolinone and benzoxazine derivatives as muscarinic M and/or M receptors agonists. This invention focuses on compounds with activity as muscarinic receptor agonists, useful in treating diseases mediated by these receptors. Furthermore, he provides pharmaceutical compositions containing these compounds alongside their therapeutic uses.

Career Highlights

Congreve's career has been marked by significant accomplishments in pharmaceutical research and development. He has held positions in reputable companies such as Heptares Therapeutics Limited and Astex Therapeutics Limited, where he played a pivotal role in advancing drug discovery and development processes.

Collaborations

Working alongside notable colleagues, including Benjamin Gerald Tehan and Giles Albert Brown, Congreve has fostered a collaborative environment that has led to numerous breakthroughs in medicinal chemistry. These partnerships have been instrumental in developing innovative solutions for complex health challenges.

Conclusion

Miles Stuart Congreve's innovative spirit and dedication to research have significantly impacted the pharmaceutical industry. His extensive patent portfolio reflects his commitment to creating effective treatments that improve patient outcomes. As he continues to explore new frontiers in drug development, his contributions remain crucial in addressing unmet medical needs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…